PSTV upcoming catalysts.

Here are some upcoming catalysts for Plus Therapeutics Inc (PSTV):

1. **Earnings Report**: PSTV is expected to report its Q3 2025 earnings on August 12, 2025. Although the earnings release date in Fiscal 2025Q3 is not disclosed, the upcoming earnings report is a significant catalyst for investors to monitor the company's financial performance.
2. **Conference Participation**: PSTV has participated in or is scheduled to participate in several conferences and meetings, such as the SNO/ASCO CNS Metastases Conference, the Society for Neuro Oncology and American Society of Clinical Oncology CNS Metastases Conference, and the San Antonio Breast Cancer Symposium. These events can provide opportunities for the company to showcase its advancements and interact with stakeholders.
3. **Clinical Trial Updates**: The company's REYOBIQ dose optimization trial for patients with leptomeningeal metastases is a key clinical catalyst. Updates on this trial could provide insights into the efficacy and progress of PSTV's lead asset.
4. **Diagnostic Platform Launch**: The launch of CNSide's CSF Assay platform in Q3 2025 is a notable catalyst. This platform aims to address the $6 billion diagnostic market and could contribute to PSTV's revenue generation capabilities.
5. **Financing and Strategic Moves**: The company's recent restructuring and securing of non-dilutive funding, along with cost-cutting measures, have stabilized its financial balance sheet. Any further developments or announcements regarding financing or strategic partnerships could impact investor sentiment.

These upcoming catalysts highlight PSTV's ongoing efforts to advance its therapeutic and diagnostic platforms, as well as its strategic financial management. Investors should monitor these events closely for potential insights into PSTV's future performance and direction.